Omnicare Inc

Omnicare — Investor Presentation (March 2012)

19 slides from Omnicare's investor presentation, Mar 6, 2012

  1. Slide 1: March 6, 2012

    March 6, 2012

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Forward-looking Statements Cx . the F ‘Securities Litigation Reform Act of 1995. These forward-looking a fof or ‘ k uncertainties i th i iffer materially The most significant is intie mpany m 10-K, Form 10-Q and Form 8-K -_ iS Commission. 6 redictic y differ materially. as

  3. Slide 3: Value Creation

    Value Creation

  4. Slide 4: Sizing Up the Business

    Sizing Up the Business (in $ mitions) 2011 2011 Revenue: Adjusted Operating Income") 1 € Pa) Long-Term Care Group Specialty Care Grouy Other/Corporate (Includes Interest Expense) Excudes special tems. Financial internation’ om the vests page

  5. Slide 5: Transitioning to an Operations-Driven Company

    Transitioning to an Operations-Driven Company Focus on Three Core Operating Objectives Establish organic growth within our Long-Term Care Group Create more standardization across the company Reposition Specialty Care Group for an elevated level of growth

  6. Slide 6: Establish Organic Growth within LTC

    Transitioning to an Operations-Driven Company Establish Organic Growth within LTC Quarterly Net Organic Bed Gain/Loss 2011 vs. 2010 8,000 (8,000) (16,000) (24,000) S6.6xbetter Byes] thanz010 2 a Q 2010 Net Organic Bed Gain/Loss 42011 Net Organic Bed Gain/Loss

  7. Slide 7: Creating More Standardization

    Transitioning to an Operations-Driven Company Creating More Standardization * Operating efficiencies — Benchmarking — Insourcing — Six Sigma-Focused Culture Technological improvements — Automation ALV/ULV Estimated Script Volume as % of Omnicare’s Long-Term Care Scripts 71.2% 63.4% — Customer-facing

  8. Slide 8: Omnicare's secure web-based worksite for customers

    Omnicare’s secure web-based worksite for customer ; and

  9. Slide 9: Specialty Drug Market Characteristics

    Specialty Drug Market Characteristics Unique Solutions to Complex Disease States Specialty product characteristics 2010 FDA Approvals — Annual cost of therapy ($25,000 40 to $150,000 per year) 30 | — Patient population (ranging from a hundreds to 250,000) 0 — Route of administration New Products New

  10. Slide 10: Specialty Care Group

    Specialty Care Group Business Model, Economics Vary Depending Upon Operational Platform Brand Supply Patient Support Chain Services Solutions Specialty End of Life Care Support Pharmacy Services Customer Third Party Payers Revenue Fee for Service Model Per Diem del Product Manufacturer owns the prod

  11. Slide 11: Repositioning Specialty Care Group for Elevated Growth

    Transitioning to an Operations-Driven Company Repositioning Specialty Care Group for Elevated Growth Omnicare specialty care growth has been robust. ..and opportunities exist to further accelerate growth through: * Continued improvements to the organizational structure - made in ale: izatic — Platfo

  12. Slide 12: Compelling Avenues for Growth

    Compelling Avenues for Growth Organic Growth New Therapeutic Categories Industry New Growth Operating Rates Platforms Adjacent Aging Markets Population

  13. Slide 13: Fourth Quarter 2011 Highlights

    Fourth Quarter 2011 Highlights Gross profit increased 3.9% sequentially to $359.7M on 0.8% increase in sales — Gross margin sequentially higher by 69 bps to 23.1%, reflecting a higher generic dispensing rate Adjusted EBITDA") increased 3.6% sequentially to $162.9M Adjusted EPS") of $0.58 vs. $0.54 i

  14. Slide 14: Focus on Cash Flow

    Focus on Cash Flow Significant Amount of Earnings Converted into Cash Flow Adjusted EBITDA from Continuing Operations vs. Cash Flows (3) (in $ millions) 2009 2010 2011 S EBITDA “CFFO &FCF Data fom te iestos’ page 2, aloes discontinued operations rotrtet equi website under Suplemental Financia Dat’ f

  15. Slide 15: Cash flow generation is expected to be redeployed toward growth drivers

    > Cash flow generation is expected to be redeployed toward growth drivers

  16. Slide 16: Capital Allocation

    Capital Allocation Putting Significant Cash Flows to Work Capital R (in millions, except %s) 2009 lm Dividends Paid 2010 iam YTD Share Repurchases 2011 O=% Returned

  17. Slide 17: Longer-Term Targets

    Longer-Term Targets “) es + Adjusted Diluted EPS (old methodology) pienaicrelgh eugene. three) years + Cash Flow from Operations $400-$500 million annually + Capital Returned to Shareholders Approximately 25% per year?) Focus on continued debt reduction, * Capital Structure management of maturity sc

  18. Slide 18: Value Creation

    Value Creation

  19. Slide 19: March 6, 2012

    March 6, 2012

Omnicare — Investor Presentation (March 2012) on 6ix